GlassScriptPhysician profile
Bruce Fred Friedman
NPI 1457345225
$10,462.07
in general payments reported to CMS, 2019-2025
28 companies · $3,219 in 2025
The $3,219 reported for 2025 was more than what 80% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $883 · 2021: $941 · 2022: $1,571 · 2023: $1,003 · 2024: $1,174 · 2025: $3,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662 · Consulting Fee: $1,719 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.53 |
| Consulting Fee | $1,719.00 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,393.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,371.43 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Pfizer INC. | $1,194.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $985.75 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $950.37 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $831.91 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.00 | 2019-2024 | Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $281.25 | 2019-2025 | |
| Genentech USA, INC. | $271.67 | 2019-2025 | Xolair |
| Optinose US, INC. | $260.18 | 2019-2025 | |
| Grifols USA, LLC | $193.97 | 2020-2025 | Xembify |
| Incyte Corporation | $170.54 | 2022-2025 | Opzelura |
| Alk-Abello, INC | $148.89 | 2019-2022 | |
| Octapharma USA, INC. | $143.85 | 2022-2023 | Cutaquig |
| Kaleo, INC. | $124.96 | 2019-2024 | Auvi-Q |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $111.00 | 2025 | |
| Shire North American Group INC | $93.43 | 2019 | |
| Blueprint Medicines Corporation | $81.17 | 2023-2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $73.39 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $62.03 | 2022-2024 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $47.65 | 2024 | |
| Leo Pharma INC. | $44.37 | 2022-2025 | Anzupgo |
| Azurity Pharmaceuticals, INC. | $39.85 | 2025 | Alvesco |
| Tersera Therapeutics LLC | $37.10 | 2024 | Quzyttir |
| Ars Pharmaceuticals Operations, INC. | $35.05 | 2025 | Neffy |
| Astellas Pharma US INC | $32.75 | 2024 | Cresemba |
| Eyevance Pharmaceuticals LLC | $21.54 | 2020 | |
| Pharming Healthcare, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.